Targeting sphingosine kinases in FceRI-mediated allergic responses

描述（由申请人提供）：肥大细胞通过释放多种炎症介质（包括组胺和其他预先形成的介质、从头合成的花生四烯酸代谢物（白三烯和异黄酮）以及多种促炎细胞因子和趋化因子）的能力，协调炎症细胞的募集，并启动和维持过敏反应。所有这些都已被证明在过敏性疾病（如过敏反应和哮喘）及其恶化的发病机制中起重要作用。我们最近的研究已经开始涉及有效的鞘脂代谢物，鞘氨醇-1-磷酸（S1 P）和神经酰胺-1-磷酸（C1 P）和产生它们的激酶，鞘氨醇激酶（SphK 1和SphK 2）和神经酰胺激酶（CerK），分别在调节肥大细胞的脱粒和它们分泌的趋化因子和细胞因子，和类花生酸合成（特别是PGD 2和CysLT）。该提案旨在增强对这些鞘脂代谢物和调节其在过敏反应和过敏反应中的人类肥大细胞功能水平的酶的作用的理解。我们假设SphK 1（可能还有SphK 2）是治疗过敏反应的新靶点，其中肥大细胞发挥关键作用。在目的1中，我们将证实S1 P和C1 P的参与和调节其水平的酶在放大和维持人肥大细胞的过敏反应。在目标2中，我们将确定新型抑制剂（靶向产生S1 P和C1 P的激酶）和FTY 720类似物阻断类花生酸产生对人肥大细胞功能的有效性。目的3集中于确定S1 P如何由人肥大细胞分泌。最后，在目标4中，我们将确定目标2中开发的新型抑制剂在减轻小鼠模型中的皮肤和全身过敏反应和气道高反应性中的有效性。这些研究将进一步加深我们对S1 P在协调人类肥大细胞功能和免疫反应中的关键作用的理解，为开发靶向调节其水平的酶的治疗剂提供基础，并为开发可能用于治疗各种严重的人类免疫反应（包括过敏反应和哮喘）的强效和特异性药物铺平道路。肥大细胞协调炎症细胞的募集，并启动和维持过敏反应。公共卫生相关性：该提案侧重于生物活性鞘脂代谢物在调节人类肥大细胞功能中的作用。鞘脂信号传导是人类过敏性疾病的核心，并且可能适合于治疗靶向。拟议的研究为治疗过敏性疾病提供了很大的希望。

DESCRIPTION (provided by applicant): Mast cells orchestrate the recruitment of inflammatory cells and initiate and perpetuate allergic responses through their ability to release a wide array of inflammatory mediators, including histamine and other preformed mediators, de novo synthesized arachidonic acid metabolites (leukotrienes and prostaglandins), and numerous proinflammatory cytokines and chemokines. All have been shown to play important roles in the pathogenesis of allergic disorders, such as anaphylaxis and asthma, and their exacerbation. Our recent studies have begun to implicate the potent sphingolipid metabolites, sphingosine-1-phosphate (S1P) and ceramide-1-phosphate (C1P) and the kinases that produce them, sphingosine kinases (SphK1 and SphK2) and ceramide kinase (CerK), respectively, in regulation of degranulation of mast cells and their secretion of chemokines and cytokines, and eicosanoid synthesis (particularly PGD2 and CysLT). This proposal is aimed at enhancing understanding of the roles of these sphingolipid metabolites and the enzymes that regulate their levels in human mast cell functions in allergic responses and anaphylaxis. It is our hypothesis that SphK1 (and possibly SphK2) are novel targets for the treatment of allergic responses in which mast cells play pivotal roles. In Aim 1, we will substantiate the involvement of S1P and C1P and the enzymes that regulate their levels in amplifying and perpetuating allergic responses of human mast cells. In Aim 2, we will determine the effectiveness of novel inhibitors (targeting the kinases producing S1P and C1P) and FTY720 analogues that block eicosanoid production on human mast cell functions. Aim 3 is focused on determining how S1P is secreted by human mast cells. Finally, in Aim 4, we will determine the effectiveness of the novel inhibitors developed in Aim 2 in alleviation of cutaneous and systemic anaphylaxis and airway hyper-responsiveness in murine models. These studies will further our understanding of the critical role of S1P in orchestrating human mast cell functions and immune reactions, providing the basis for development of therapeutic agents that target the enzymes that regulate its levels and "pave the way" for the development of potent and specific drugs that potentially could be useful for treating various severe human immune responses, including anaphylaxis and asthma. Mast cells orchestrate the recruitment of inflammatory cells and initiate and perpetuate allergic responses. Public Health Relevance: This proposal is focused on the role of bioactive sphingolipid metabolites in regulating functions of human mast cells. Sphingolipid signaling is central to human allergic diseases and potentially amenable to therapeutic targeting. The proposed studies hold much promise for treatment of allergic disorders.